---

🩸 HEMOSTASIS — COMPLETE NEET PG 2026 GUIDE

---

1. OVERVIEW OF HEMOSTASIS

The balance between procoagulant and anticoagulant forces determines whether clotting occurs. Normally, anticoagulants predominate in circulating blood. — Guyton & Hall Textbook of Medical Physiology

---

2. VASCULAR SPASM (First Line of Defense)

• Occurs immediately after vessel injury
• Mechanism:
  • Local myogenic spasm — direct smooth muscle response to trauma
  • Autacoid factors from injured endothelium and platelets (especially Thromboxane A₂ from platelets)
  • Neurogenic reflexes via pain impulses
• More severe injury → greater spasm
• Duration: minutes to hours — buys time for plug and clot formation

---

3. PRIMARY HEMOSTASIS — PLATELET PLUG FORMATION

Platelet Basics

• Actin + myosin + thrombostenin (contraction)
• Dense granules: ADP, ATP, serotonin, calcium
• Alpha granules: fibrinogen, vWF, fibronectin, PDGF (platelet-derived growth factor)
• Membrane phospholipids: Platelet Factor 3 (PF3) — activates coagulation
• Surface glycoproteins: GpIb (binds vWF), GpIIb/IIIa (binds fibrinogen)

Steps of Primary Hemostasis

Vascular injury
     ↓
Endothelium disrupted → Subendothelial collagen + vWF exposed
     ↓
Platelet ADHESION: GpIb receptor binds vWF (vWF acts as bridge to collagen)
     ↓
Platelet ACTIVATION:
  - Shape change (disc → spiky sphere)
  - Granule release: ADP, TXA₂, serotonin, thrombin
  - Flip of membrane phospholipids (phosphatidylserine) → procoagulant surface
  - Conformational change in GpIIb/IIIa → binds fibrinogen
     ↓
Platelet AGGREGATION: Fibrinogen bridges GpIIb/IIIa on adjacent platelets
     ↓
PRIMARY PLATELET PLUG (loose, temporary)

High-yield: Aspirin irreversibly inhibits COX-1 → ↓TXA₂ → inhibits platelet aggregation for platelet's lifetime (~10 days). Clopidogrel blocks ADP receptor (P2Y₁₂).

---

4. SECONDARY HEMOSTASIS — COAGULATION CASCADE

Coagulation Factors Overview

Mnemonic: "1972" → Factors II, VII, IX, X

The Coagulation Cascade

EXTRINSIC PATHWAY                    INTRINSIC PATHWAY (Contact)
(TF pathway — in vivo dominant)       (Surface activation)

Tissue Factor + Factor VII            XII → XIIa (contact with collagen)
        ↓                                      ↓
      VIIa-TF complex                   XI → XIa
        ↓                                      ↓
  Activates Factor X                   IX → IXa
        ↓                             IXa + VIIIa + PF3 + Ca²⁺
                                      (Tenase complex)
                                              ↓
                                       Activates Factor X
                                              ↓
                    ──── COMMON PATHWAY ────
                    
            Xa + Va + PF3 + Ca²⁺ = PROTHROMBINASE COMPLEX
                              ↓
               Prothrombin (II) → Thrombin (IIa)
                              ↓
               Fibrinogen (I) → Fibrin monomer
                              ↓
               Fibrin monomer polymerizes → Fibrin polymer (weak)
                              ↓
               XIIIa (activated by thrombin) crosslinks fibrin
                              ↓
               STABLE FIBRIN CLOT (Secondary hemostatic plug)

The Cell-Based Model of Coagulation (Modern/In Vivo View)

• TF binds Factor VII → TF:VIIa complex
• Activates small amounts of IX and X → small burst of thrombin

• Small amount of thrombin:
  • Activates platelets → GpIIb/IIIa expression
  • Activates Factor V, VIII, XI
  • Releases vWF from Weibel-Palade bodies

• IXa + VIIIa (tenase complex) → large amounts of Xa
• Xa + Va (prothrombinase) → massive thrombin burst
• Thrombin cleaves fibrinogen → fibrin clot
• Factor XIII crosslinks fibrin

Thrombin — The Central Molecule

---

5. NATURAL ANTICOAGULANT MECHANISMS

High-yield: Factor V Leiden (Arg506Gln mutation) → Protein C cannot inactivate Factor Va → most common hereditary hypercoagulable state.

---

6. FIBRINOLYSIS

Plasminogen (inactive)
      ↓ (activated by tPA, urokinase)
   Plasmin (active)
      ↓
Cleaves fibrin → Fibrin Degradation Products (FDPs) + D-dimers

• tPA (tissue plasminogen activator): released by endothelium; fibrin-bound tPA is 400× more effective
• D-dimer: specific product of crosslinked fibrin degradation → marker of active clot turnover (used in DVT/PE workup)
• α₂-antiplasmin: inhibits plasmin in circulation (prevents systemic fibrinolysis)
• PAI-1 (Plasminogen Activator Inhibitor-1): inhibits tPA → pro-thrombotic; elevated in metabolic syndrome

---

7. TESTS OF HEMOSTASIS

A. Platelet Assessment

B. Coagulation Tests

INR Formula:

Mixing Studies (Correction Test)

C. Tests for Primary vs Secondary Hemostasis

---

8. PROTOCOLS FOR COAGULATION TESTING (NEET PG High-Yield)

When to Order What

Thromboelastography (TEG) / ROTEM

• Viscoelastic whole blood tests — assess clot formation in real time
• Measures: clotting time, clot formation rate, clot strength, fibrinolysis
• Used in: cardiac surgery, trauma, liver transplantation
• Advantage: captures platelet function + coagulation + fibrinolysis together

---

9. SUMMARY — DISORDERS OF HEMOSTASIS

A. Thrombocytopenia (↓ Platelet Count)

TTP vs HUS: TTP = ADAMTS13 ↓, CNS dominant; HUS = complement/Shiga toxin, renal dominant; both = MAHA + thrombocytopenia

B. Platelet Function Disorders

Mnemonic for Bernard-Soulier vs Glanzmann: Soulier = Stuck (can't adhere); Glanzmann = Grouped (can't aggregate)

C. Coagulation Factor Disorders

D. Hypercoagulable States (Thrombophilias)

E. DIC — Disseminated Intravascular Coagulation

Systemic TF expression (e.g., LPS, cytokines, amniotic fluid)
        ↓
Widespread thrombin generation
        ↓
Microvascular fibrin thrombi → organ ischemia
+ Consumption of factors I, V, VIII, and platelets
        ↓
BLEEDING (paradoxical) + MAHA (RBC fragmented by fibrin strands = schistocytes)

DIC vs liver disease: Factor VIII is low in DIC but normal in liver disease. vWF is ↑ in liver disease (acute phase reactant from endothelium). FDPs/D-dimer markedly ↑ in DIC.

---

10. QUICK RECALL TABLE — HIGH-YIELD NEET PG FACTS

---

11. CLINICAL CORRELATION — BLEEDING PATTERNS

---

• Guyton & Hall Textbook of Medical Physiology, 14th Ed — Chapter 37 (Hemostasis and Blood Coagulation)
• Robbins & Kumar Basic Pathology (Robbins Pathology) — Hemostasis, Bleeding Disorders chapters
• Schwartz's Principles of Surgery, 11th Ed — Tests of Hemostasis and Blood Coagulation

---

🩸 HEMOSTASIS — CONTINUATION (DEEP DIVE)

---

12. DETAILED DISORDERS OF HEMOSTASIS

---

A. DISSEMINATED INTRAVASCULAR COAGULATION (DIC)

Pathogenesis — In Detail

• Obstetric complications: placental abruption, amniotic fluid embolism, retained dead fetus
• Malignancy: Acute Promyelocytic Leukemia (APL/M3) — azurophilic granules release procoagulants; also adenocarcinomas (lung, pancreas, colon, stomach) — mucin directly activates Factor X
• Major trauma / burns / surgery
• Snake venom

• Sepsis (most common): LPS/endotoxin → monocytes express TF; TNF → endothelial TF expression + ↓thrombomodulin → unchecked thrombin generation
• Immune complexes (SLE)
• Temperature extremes (heat stroke)
• Organisms: meningococci, rickettsiae

Pathophysiology — Two Consequences

TRIGGER (TF release or endothelial injury)
           ↓
  Systemic thrombin generation
           ↓
    ┌──────────────────────────────────┐
    │                                  │
Fibrin microthrombi             Consumption of platelets,
  in microcirculation           fibrinogen, factors V, VIII
  → Ischemia/infarcts           + Secondary fibrinolysis activation
  → Microangiopathic                  ↓
    hemolytic anemia (MAHA)     BLEEDING DIATHESIS
    (RBCs sheared by fibrin          (paradox)
     strands = schistocytes)

In bacterial sepsis, TNF upregulates TF on endothelial cells and simultaneously downregulates thrombomodulin, tipping the balance toward coagulation. — Robbins, Cotran & Kumar Pathologic Basis of Disease

Organs Affected (in descending frequency)

• Kidneys: glomerular thrombi → bilateral renal cortical necrosis (severe DIC)
• Adrenals: hemorrhagic necrosis → Waterhouse-Friderichsen syndrome (meningococcal sepsis)
• Skin: petechiae, ecchymoses, purpura fulminans

Clinical Presentation

Laboratory Diagnosis of DIC

DIC vs Liver Disease — Differentiating Key

DIC vs TTP/HUS

Treatment of DIC

1. Treat the underlying cause — always primary
2. Active bleeding: FFP (replaces all factors) + cryoprecipitate (if fibrinogen <150 mg/dL) + platelet transfusion (if count <50,000 + active bleeding)
3. Dominant thrombosis (chronic DIC): low-dose heparin (50 U/kg IV q6h)
4. Do NOT correct lab abnormalities in non-bleeding patients

---

B. THROMBOCYTOPENIA — CLASSIFICATION & KEY Disorders

Causes of Thrombocytopenia

---

C. IMMUNE THROMBOCYTOPENIC PURPURA (ITP)

Pathogenesis

• Autoantibodies (IgG) against GpIIb/IIIa (or GpIb) on platelet surface
• Opsonized platelets destroyed in spleen (extravascular hemolysis)
• Bone marrow: ↑ megakaryocytes (compensatory)

Types

Clinical Features

• Petechiae, purpura, mucosal bleeding
• No splenomegaly (key differentiator from other causes)
• Platelet count < 50,000 (often <20,000 in severe cases)
• Normal PT, normal aPTT, prolonged BT

Lab

• Antiplatelet antibodies (anti-GpIIb/IIIa)
• Bone marrow: megakaryocytes increased

Treatment

• Mild: Observation
• First-line: Corticosteroids (prednisolone 1 mg/kg/day)
• IVIG: rapid response needed (surgery, severe bleeding)
• Splenectomy: second-line (removes site of destruction + antibody production)
• Refractory: Rituximab (anti-CD20), TPO agonists (romiplostim, eltrombopag)

---

D. HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)

Two Types

The 4T score (Thrombocytopenia magnitude, Timing, Thrombosis, alternative cause) is used to assess pre-test probability of HIT.

---

E. THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)

Pathogenesis

ADAMTS13 deficiency (congenital or acquired autoantibody)
        ↓
Ultra-large vWF multimers accumulate in blood
        ↓
Spontaneous platelet aggregation in microvasculature
        ↓
Platelet-rich thrombi in arterioles and capillaries
        ↓
Platelet consumption (thrombocytopenia) + RBC fragmentation (MAHA/schistocytes)
        ↓
Organ ischemia: brain (neurologic sx), kidneys (renal failure)

Classic Pentad (TTP)

1. Fever
2. Anemia (microangiopathic hemolytic anemia / MAHA)
3. Thrombocytopenia
4. Renal failure
5. Neurologic dysfunction (headache, confusion, seizures, stroke)

In practice, complete pentad seen in <30% of cases. Triad (MAHA + thrombocytopenia + neurologic sx) is sufficient to initiate treatment.

Labs

• ADAMTS13 activity <10% (diagnostic)
• Normal PT, normal aPTT (no coagulation cascade activation — key!)
• Schistocytes on peripheral smear
• LDH ↑↑ (hemolysis + tissue ischemia)
• Haptoglobin ↓
• Indirect bilirubin ↑
• Direct Coombs test: Negative (mechanical hemolysis, not immune)

Treatment

• Plasma exchange (plasmapheresis) — first-line; replaces ADAMTS13 + removes antibody
• Steroids (immunosuppression)
• Rituximab for refractory/relapsing cases
• Caplacizumab — anti-vWF nanobody; new targeted therapy
• Platelet transfusion: CONTRAINDICATED ("fuel on fire" → more thrombi)

---

F. HEMOLYTIC UREMIC SYNDROME (HUS)

Pathogenesis

• Typical HUS: Shiga toxin from E. coli O157:H7 (STEC-HUS) or Shigella dysenteriae
  • Toxin damages glomerular endothelium → platelet activation → microthrombi in glomeruli
• Atypical HUS (aHUS): Complement regulatory protein mutations (Factor H, Factor I, MCP/CD46) → uncontrolled complement activation → endothelial injury

Clinical Features (Triad)

1. Microangiopathic hemolytic anemia (MAHA)
2. Thrombocytopenia
3. Acute renal failure (dominant — more so than TTP)

Preceded by bloody diarrhea (STEC-HUS) or respiratory infection. Most common cause of acute renal failure in children.

Treatment

• Supportive: fluids, dialysis if needed
• Eculizumab (anti-C5 monoclonal antibody) for atypical HUS
• Avoid antibiotics in STEC-HUS (↑ Shiga toxin release → worsens HUS)
• Platelet transfusion: Contraindicated

---

G. von WILLEBRAND DISEASE (vWD)

Background

• Most common hereditary bleeding disorder (~1% of population)
• vWF functions:
  1. Bridges platelet GpIb to subendothelial collagen (adhesion)
  2. Carries and stabilizes Factor VIII in plasma (vWF t½ increase from 2.4h → 12h)
• vWF made by: endothelial cells (Weibel-Palade bodies) and megakaryocytes (platelet α-granules)

Classification of vWD

Clinical Features

• Mucosal bleeding: epistaxis, menorrhagia, gingival bleeding, GI bleeding
• Easy bruising
• Prolonged BT, prolonged PFA-100
• aPTT: mildly prolonged (Type 1, 2, 3) — because vWF carries VIII
• PT: normal

Key Diagnostic Tests

Type 2B high-yield trap: Ristocetin causes MORE aggregation than normal (abnormal gain-of-function) — but clinically there is thrombocytopenia and bleeding.

Treatment

---

H. HEMOPHILIA A (Factor VIII Deficiency)

Genetics & Epidemiology

• X-linked recessive; males affected; females are carriers (rarely symptomatic due to lyonization)
• 30% have no family history (new mutations)
• Most common severe hereditary bleeding disorder
• Most common mutation in severe disease: inversion of intron 22 of Factor VIII gene

Severity Classification

Clinical Features

• Hemarthrosis (bleeding into joints) → most common site = knees > elbows > ankles
• Recurrent hemarthrosis → chronic synovitis → joint deformity (target joint)
• Deep muscle hematomas
• Retroperitoneal hematomas
• Post-circumcision/dental bleeding
• Intracranial hemorrhage (leading cause of death)
• No petechiae (primary hemostasis intact — platelets normal)

Labs

• aPTT: prolonged
• PT: normal
• BT: normal
• Platelet count: normal
• Mixing study: corrects (factor deficiency)
• Factor VIII assay: ↓

Treatment

• Recombinant Factor VIII concentrate (standard)
• Desmopressin (DDAVP): only in mild hemophilia A — releases stored FVIII; raises levels 2–3× — not effective in severe disease
• Emicizumab (Hemlibra): bispecific antibody mimicking FVIIIa — links FIXa and FX; effective even if inhibitors present; subcutaneous
• Inhibitors (15% of severe HA): IgG antibodies neutralize FVIII → treat with bypassing agents (aPCC, recombinant FVIIa)
• Avoid NSAIDs, IM injections
• Cryoprecipitate: contains FVIII, vWF, fibrinogen, FXIII — used if recombinant factor unavailable

---

I. HEMOPHILIA B (Factor IX Deficiency / Christmas Disease)

• X-linked recessive; clinically identical to Hemophilia A
• Diagnosis: ↑aPTT, normal PT; specific Factor IX assay
• Treatment: Recombinant Factor IX concentrate
• Desmopressin ineffective in Hemophilia B
• Eftrenonacog alfa / fitusiran — newer therapies

Distinguish Hemophilia A from B: only specific factor assays differentiate — aPTT pattern is identical.

---

J. FACTOR XIII DEFICIENCY

• Normal PT and aPTT — most important feature
• Fibrin clot forms but is not crosslinked → dissolves in 5M urea or 1% monochloroacetic acid
• Clinical: poor wound healing, recurrent miscarriages, umbilical stump bleeding in neonates, delayed rebleeding after trauma
• Treatment: FFP, cryoprecipitate, or Factor XIII concentrate

---

K. HYPERCOAGULABLE STATES (THROMBOPHILIAS) — DETAILED

Inherited Thrombophilias

Antiphospholipid Syndrome (APS)

• ≥3 unexplained consecutive miscarriages (<10 weeks)
• ≥1 unexplained fetal death (≥10 weeks)
• ≥1 premature birth (<34 weeks) due to eclampsia/placental insufficiency

• Thrombosis: heparin (acute) → warfarin (long-term, INR 2–3)
• Pregnancy: LMWH + low-dose aspirin (warfarin teratogenic)
• Catastrophic APS (CAPS): multiorgan failure; triple therapy — heparin + steroids + IVIG/plasmapheresis

---

13. PLATELET FUNCTION DISORDERS — EXPANDED

Bernard-Soulier Syndrome (BSS)

Glanzmann Thrombasthenia

Comparison Table

---

14. ANTICOAGULANT THERAPY — MECHANISMS & MONITORING

Heparin (Unfractionated Heparin, UFH)

Low Molecular Weight Heparin (LMWH — Enoxaparin, Dalteparin)

Warfarin

Direct Oral Anticoagulants (DOACs)

Antiplatelet Drugs

---

15. SPECIFIC HIGH-YIELD NEET PG EXAM TRAPS

---

16. CRYOPRECIPITATE vs FFP vs Platelets — WHAT EACH CONTAINS

---

17. VIRCHOW'S TRIAD AND THROMBOSIS

---

18. PLATELET GRANULE CONTENTS — COMPLETE

• ADP → P2Y₁₂ receptor → ↑aggregation
• TXA₂ (synthesized on activation) → TP receptor → aggregation + vasoconstriction
• Serotonin → vasoconstriction

---

19. FIBRINOLYTIC SYSTEM — COMPLETE

FIBRINOLYTIC SYSTEM

Endothelium releases tPA (tissue plasminogen activator)
         ↓
tPA cleaves plasminogen → PLASMIN
         ↓
Plasmin degrades:
  - Fibrin → FDPs (Fibrin Degradation Products)
  - D-dimer (from crosslinked fibrin only)
  - Factors V and VIII (reducing coagulation further)

REGULATORY MECHANISMS:
  α₂-antiplasmin → inactivates free plasmin in circulation
  PAI-1 → inhibits tPA (↑ in metabolic syndrome, pregnancy → pro-thrombotic)
  TAFI (Thrombin Activatable Fibrinolysis Inhibitor) → activated by thrombin-thrombomodulin → protects clot from lysis

---

20. SUMMARY MASTER TABLE — ALL DISORDERS

---

• Guyton & Hall Textbook of Medical Physiology, 14th Ed
• Robbins & Kumar Basic Pathology (Robbins Pathology)
• Robbins, Cotran & Kumar Pathologic Basis of Disease (Big Robbins)
• Schwartz's Principles of Surgery, 11th Ed
• Harrison's Principles of Internal Medicine, 22nd Ed